Clinical trial

Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics

Name

NAVE003220HU

Description

The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.

Trial arms

Trial start

2010-07-01

Estimated PCD

2011-12-01

Trial end

2011-12-01

Status

Completed

Treatment

D-cycloserine

50 mg d-cycloserine, oral, 1 dose

Arms:

D-cycloserine plus exposure therapy

Exposure therapy

Single session graded in vivo exposure therapy, 60-180 minutes

Arms:

D-cycloserine plus exposure therapy, Placebo plus exposure therapy

Placebo

Single capsule of oral placebo, administered once 1 hr prior to exposure therapy

Arms:

Placebo plus exposure therapy

Size

Primary endpoint

Snake Questionnaire (SNAQ)

2 weeks

Eligibility criteria

Inclusion Criteria: * Primary diagnosis of specific phobia (snakes) Exclusion Criteria: * History of psychosis, obsessive-compulsive disorder, or mania * Recent substance abuse or suicidality * Previous receipt of study treatments

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 20, 'type': 'ACTUAL'}}

Updated at

2024-03-15

1 organization

1 product

1 drug

1 indication

Organization

Product

Indication

Drug